Mieke Ptaszynski

407 total citations
22 papers, 320 citations indexed

About

Mieke Ptaszynski is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Mieke Ptaszynski has authored 22 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Molecular Biology and 8 papers in Hematology. Recurrent topics in Mieke Ptaszynski's work include Protein Degradation and Inhibitors (6 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer Treatment and Pharmacology (5 papers). Mieke Ptaszynski is often cited by papers focused on Protein Degradation and Inhibitors (6 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer Treatment and Pharmacology (5 papers). Mieke Ptaszynski collaborates with scholars based in United States, Serbia and Spain. Mieke Ptaszynski's co-authors include Kevin Litwiler, H. Jean Khoury, Heidi Simmons, Hagop M. Kantarjian, Jeffrey A. Zonder, Brandi Hilder, Jonathan L. Kaufman, Duncan Walker, Brian Tunquist and Adam I. Marcus and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Mieke Ptaszynski

21 papers receiving 314 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mieke Ptaszynski United States 10 210 119 112 87 40 22 320
Matthew D. Storck United States 10 151 0.7× 58 0.5× 47 0.4× 22 0.3× 20 0.5× 19 246
AC Bloem Netherlands 8 242 1.2× 154 1.3× 69 0.6× 282 3.2× 11 0.3× 10 459
Anastasia S. Proskurina Russia 12 144 0.7× 170 1.4× 26 0.2× 44 0.5× 29 0.7× 62 388
Lilach Gutter-Kapon Israel 6 305 1.5× 139 1.2× 240 2.1× 29 0.3× 22 0.6× 6 477
Athanasios Papadas United States 7 126 0.6× 175 1.5× 75 0.7× 22 0.3× 56 1.4× 11 336
Emma Risson United States 4 142 0.7× 189 1.6× 57 0.5× 19 0.2× 40 1.0× 5 325
Е. В. Долгова Russia 13 153 0.7× 175 1.5× 24 0.2× 55 0.6× 29 0.7× 55 403
Ilanit Boyango Israel 11 407 1.9× 84 0.7× 417 3.7× 31 0.4× 28 0.7× 16 582
Florian Bonin France 8 153 0.7× 112 0.9× 43 0.4× 21 0.2× 53 1.3× 11 289
Aicha El Bakkali Spain 5 169 0.8× 135 1.1× 87 0.8× 13 0.1× 96 2.4× 5 314

Countries citing papers authored by Mieke Ptaszynski

Since Specialization
Citations

This map shows the geographic impact of Mieke Ptaszynski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mieke Ptaszynski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mieke Ptaszynski more than expected).

Fields of papers citing papers by Mieke Ptaszynski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mieke Ptaszynski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mieke Ptaszynski. The network helps show where Mieke Ptaszynski may publish in the future.

Co-authorship network of co-authors of Mieke Ptaszynski

This figure shows the co-authorship network connecting the top 25 collaborators of Mieke Ptaszynski. A scholar is included among the top collaborators of Mieke Ptaszynski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mieke Ptaszynski. Mieke Ptaszynski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abramson, Vandana G., Pavani Chalasani, Hannah M. Linden, et al.. (2022). Abstract P1-17-02: ZN-c5, an oral selective estrogen receptor degrader (SERD), in women with advanced estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Cancer Research. 82(4_Supplement). P1–17. 11 indexed citations
2.
3.
Chalasani, Pavani, Vandana G. Abramson, Joanne Mortimer, et al.. (2021). Abstract PS12-20: A dose escalation study of the novel oral SERD-ZN-c5 in women with ER-positive, HER2-negative advanced/metastatic breast cancer. Cancer Research. 81(4_Supplement). PS12–20. 3 indexed citations
4.
5.
Turner, Nicholas C., Ian E. Krop, Aditya Bardia, et al.. (2020). Abstract OT2-07-01: A phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor (FGFR) amplifications (FOENIX-MBC2). Cancer Research. 80(4_Supplement). OT2–7. 3 indexed citations
6.
Shah, Jatin J., Jonathan L. Kaufman, Jeffrey A. Zonder, et al.. (2017). A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma. Cancer. 123(23). 4617–4630. 48 indexed citations
7.
Chari, Ajai, Myo Htut, Jeffrey A. Zonder, et al.. (2016). A phase 1 dose‐escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma. Cancer. 122(21). 3327–3335. 33 indexed citations
8.
Ocio, Enrique M., Paula Rodríguez‐Otero, Joaquín Martínez‐López, et al.. (2016). Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group. Blood. 128(22). 4503–4503. 5 indexed citations
9.
LoRusso, Patricia, Priscila Gonçalves, Kevin Litwiler, et al.. (2015). First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. Investigational New Drugs. 33(2). 440–449. 40 indexed citations
10.
Garcia‐Manero, Guillermo, H. Jean Khoury, Elias Jabbour, et al.. (2014). A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes. Clinical Cancer Research. 21(5). 985–994. 40 indexed citations
11.
Khoury, H. Jean, Guillermo Garcia‐Manero, Gautam Borthakur, et al.. (2011). A phase 1 dose‐escalation study of ARRY‐520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer. 118(14). 3556–3564. 56 indexed citations
12.
Ellard, Susan, Mace L. Rothenberg, Roger Cohen, et al.. (2009). Abstract #3603: ARRY-334543 in ErbB2 positive metastatic breast cancer and other ErbB expressing-cancers: experience from expansion cohorts on a phase I study. Cancer Research. 69. 3603–3603. 2 indexed citations
13.
Estrov, Zeev, Jörge E. Cortes, Gautam Borthakur, et al.. (2009). A phase I dose-escalation study of the novel KSP inhibitor ARRY-520 in advanced leukemias. Journal of Clinical Oncology. 27(15_suppl). 7022–7022. 2 indexed citations
14.
Garcia‐Manero, Guillermo, H. Jean Khoury, Gautam Borthakur, et al.. (2009). A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias.. Blood. 114(22). 2047–2047. 2 indexed citations
15.
Poole, C. J., M. Gore, P. Vasey, et al.. (2005). Randomized phase II parallel evaluation of OSI-211 (liposomal lurtotecan) and topotecan in women with relapsed epithelial ovarian cancer (EOC). Journal of Clinical Oncology. 23(16_suppl). 5017–5017. 2 indexed citations
16.
Clark, Gary M., Pablo J. Cagnoni, Mieke Ptaszynski, et al.. (2005). P-946 Why do non smokers with non-small cell lung cancer (NSCLC) who receive erlotinib have better clinical outcomes than smokers?. Lung Cancer. 49. S368–S368. 2 indexed citations
17.
Gelmon, Karen A., Hal W. Hirte, B. Fisher, et al.. (2004). A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Investigational New Drugs. 22(3). 263–275. 22 indexed citations
18.
MacKenzie, Mary J., Hal W. Hirte, Lillian L. Siu, et al.. (2004). A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Annals of Oncology. 15(4). 665–670. 10 indexed citations
19.
Desjardins, John, David L. Emerson, Blake Tomkinson, et al.. (2001). Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice. Anti-Cancer Drugs. 12(3). 235–245. 15 indexed citations
20.
Kehrer, Diederik F.S., Arie Bos, Alex Sparreboom, et al.. (1999). Clinical pharmacokinetics of liposomal lurtotecan (NX211) in whole blood, plasma and urine.. Data Archiving and Networked Services (DANS). 5.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthew D. Storck Breakdown of academic impact, for papers by AC Bloem Breakdown of academic impact, for papers by Anastasia S. Proskurina Breakdown of academic impact, for papers by Lilach Gutter-Kapon Breakdown of academic impact, for papers by Athanasios Papadas Breakdown of academic impact, for papers by Emma Risson Breakdown of academic impact, for papers by Е. В. Долгова Breakdown of academic impact, for papers by Ilanit Boyango Breakdown of academic impact, for papers by Florian Bonin Breakdown of academic impact, for papers by Aicha El Bakkali
Rankless by CCL
2026